Low T3 Would Indicate Adverse Outcomes for Inpatients with Decompensated Heart Failure

Lucrecia Secco, Silvana Mettini, Cecilia Cejas, Cecilia Biglia, Dario A. Fernández, Stella M. Pereiro González


Background: Low T3 syndrome is associated with elevated circulating levels of cytokines and interleukins, reinforcing thehypothesis of a close relation between the neuroendocrine system and certain inflammatory and immunological mechanismsinvolved in heart failure.Objective: To assess the progress of patients admitted for decompensated heart failure according to T3 levels on admission,and events during hospitalization and follow-up.Materials and methods: It was a prospective, observational, analytical study of 524 patients hospitalized for the first timewith a diagnosis of decompensated heart failure. In-hospital and follow-up mortality and readmissions were evaluated accordingto normal or low T3 levels on admission. Ninety-one patients with known dysthyroidism, hypo or hyperthyroidism,previous thyroid surgery, sepsis or acute coronary syndrome were excluded. A subgroup analysis of patients receiving chronicamiodarone therapy was conducted, and prognostic variables were evaluated.Results: Of the 433 patients analyzed, 40.0% had low T3 (LT3) levels. Age, albumin level, age >75 years, and glomerularfiltration rate (GFR) were independent predictors of LT3. While adaptation of guideline-recommended treatments increasedin both groups, treatment rates in the LT3 group were significantly lower than those in the normal T3 (NT3) group (LT3vs. NT3: Betablockers 81.5% vs. 89.4%, p=0.02; ACEI/ARA II 78.5% vs. 87.9%, p=0.001; anti-aldosterone agents 29.2% vs.40.5%; p=0.019). Hospital mortality was higher in the LT3 group (5.8 vs. 1.5%), with no difference in rehospitalizations ormortality rates at follow-up. Of the subgroup of patients without amiodarone on admission (353), 37.8% had LT3. Patientsin this subgroup were found to have significant differences in follow-up and in-hospital mortality (5.3% in LT3 vs. 0.9% inNT3, p=0.03, and 40.2% vs. 26.6%, p=0.023) respectively.Conclusions: Decompensated heart failure patients with LT3 on admission would represent a subgroup with more severedisease and worse prognosis during hospitalization.


Ascheim DD, Hryniewicz K. Thyroid hormone metabolism in patients with with congestive heart failure: The low triiodothyronine state.Thyroid 2002;12:511-5. http://doi.org/10.1089/105072502760143908

Giorgio Iervasi, Alessandro Pingitore, Patrizia Landi, Mauro

Raciti, Andrea Ripoli, Maria Scarlattini, et al. Low-T3 Syndrome.

A Strong Prognostic Predictor of Death in Patients with Heart Disease. Circulation 2002;107:708-13. http://doi.org/10.1161/01.CIR.0000048124.64204.3F

Biondi B. Review. Heart failure and thyroid dysfunction. Eur J

Endocrinol 2012;167:609-18. http://doi.org/10.1530/EJE-12-0627

Fairman E, Pereiro González SM. Disfunción tiroidea en insuficiencia cardíaca. Comorbilidades en la insuficiencia Cardíaca crónica.En: Comorbilidades en la insuficiencia cardíaca crónica / Fernández, Alberto; Barisani, José Luis; Fairman, Enrique. 1ª ed. Buenos Aires:Inter-Médica, 2017; VII, 94-104.

Rothberger GD, Gadhvi S, Michelakis N, Kumar A, Calixte R, ShapiroLE. Usefulness of Serum Triiodothyronine (T3) to Predict Outcomes in Patients Hospitalized With Acute Heart Failure. Am J Cardiol 2017;119:599-603. http://doi.org/10.1016/j.amjcard.2016.10.045

Wang W, Guan H, Gerdes AM, Iervasi G, Yang Y, Tang YD. Thyroid Status, Cardiac Function, and Mortality in Patients With Idiopathic Dilated Cardiomyopathy. J Clin Endocrinol Metab. 2015;100:3210-8. https://doi.org/10.1210/jc.2014-4159

Klein I, Ojamaa K. Thyroid hormone and the cardiovascular

system. N Engl J Med. 2001;344:501-9. http://doi.org/10.1056/NEJM200102153440707.

Dillmann WH. Cellular action of thyroid hormone on the heart.

Thyroid 2002;12:447-52. http://doi.org/10.1089/105072502760143809

Galli E, Pingitore A, Iervasi G. The role of thyroid hormone in the

pathophysiology of heart failure: clinical evidence. Heart Fail Rev.

;15:155-69. http://doi.org/ 10.1007/s10741-008-9126-6

Pingitore A, Galli E, Barison A, Iervasi A, Scarlattini M, Nucci D,

et al. Acute effects of triiodothyronine (T3) replacement therapy in patients with chronic heart failure and low-T3 syndrome: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008;93:1351-8. http://doi.org/10.1210/jc.2007-2210

Farwell AP. Thyroid hormone therapy is not indicated in the

majority of patients with the sick euthyroid syndrome. Endocr Pract

;14:1180-7. http://doi.org/ 10.4158/EP.14.9.1180

Sato Y, Yoshihisa A, Kimishima Y, Kiko T, Kanno Y, Yokokawa T,

et al. Low T3 Syndrome Is Associated With High Mortality in Hospitalized Patients With Heart Failure. J Card Fail 2019;25:195-203. https://doi.org/10.1016/j.cardfail.2019.01.007

Full Text


  • There are currently no refbacks.

Licencia Creative Commons
The documents published in this journal are under the licencia Creative Commons Atribución-NoComercial-Compartir-Igual 2.5 Argentina.

Revista argentina de cardiología. ISSN en línea 1850-3748. Argentine journal of cardiology (English ed. Online ISSN 2314-2286) Sociedad Argentina de Cardiología. Azcuénaga 980 (C1115AAD),Ciudad Autónoma de Buenos Aires, República Argentina. Tel. (54 11) 4961-6027/8/9 Fax: 4961-6020 www.sac.org.ar revista@sac.org.ar